Share Email Print
cover

Proceedings Paper

Testing of efficacy of photodynamic therapy with a new photosensitizer: a derivative of chlorin e6 (BLC 1010)
Author(s): Eugeny Ph. Stranadko; Michail V. Riabov; N. N. Volkova; S. Spaniol; W. Rauschning; N. E. Nifantiev
Format Member Price Non-Member Price
PDF $14.40 $18.00
cover GOOD NEWS! Your organization subscribes to the SPIE Digital Library. You may be able to download this paper for free. Check Access

Paper Abstract

Efficacy of PDT with new chlorin e6 photosensitizer (BLC 1010) has been tested in 72 cancer patients. 44 patients (61 %) achieved a complete response and 39 % of the patients a partial response (28 patients, including 15 patients treated for palliation). Rapid elimination of BLC 1010 from the organism solves the problem of skin phototoxicity encountered in PDT up to now. This property together with its high tumor to normal ratio makes it a promising photosensitizer for PDT. Further advantage is that portable diode lasers with proper wavelength are available.

Paper Details

Date Published: 26 October 2001
PDF: 3 pages
Proc. SPIE 4433, Laser-Tissue Interactions, Therapeutic Applications, and Photodynamic Therapy, (26 October 2001); doi: 10.1117/12.446519
Show Author Affiliations
Eugeny Ph. Stranadko, State Research Ctr. for Laser Medicine (Russia)
Michail V. Riabov, State Research Ctr. for Laser Medicine (Russia)
N. N. Volkova, State Research Ctr. for Laser Medicine (Russia)
S. Spaniol, BioLitec AG (Germany)
W. Rauschning, BioLitec AG (Germany)
N. E. Nifantiev, BioLitec AG (Germany)


Published in SPIE Proceedings Vol. 4433:
Laser-Tissue Interactions, Therapeutic Applications, and Photodynamic Therapy
Reginald Birngruber; Hubert van den Bergh, Editor(s)

© SPIE. Terms of Use
Back to Top